Imatinib exhibited broad systemic effects, with strong associations to cardiovascular (hypertension), metabolic (diabetes), and neuropsychiatric (schizophrenia and depression) conditions, consistent with its multi-kinase inhibition profile, targeting PDGFR and c-KIT. Here, PDGFRB is linked to schizophrenia.